A5101527594- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Inflammatory Bowel Disease
- Eosinophilic Esophagitis
- Microscopic Colitis
- Pregnancy and preeclampsia studies
- Socioeconomic Development in Asia
- Autoimmune and Inflammatory Disorders
- Adolescent and Pediatric Healthcare
- Endometriosis Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Liver Diseases and Immunity
- Immunodeficiency and Autoimmune Disorders
- Diverticular Disease and Complications
- Pharmaceutical studies and practices
- Pelvic floor disorders treatments
- Diagnosis and treatment of tuberculosis
- Mobile Health and mHealth Applications
- Anorectal Disease Treatments and Outcomes
- COVID-19 and healthcare impacts
- Biliary and Gastrointestinal Fistulas
- German History and Society
- Gallbladder and Bile Duct Disorders
- Nutrition and Health in Aging
- Bioinformatics and Genomic Networks
University of California, San Francisco
2016-2025
Hindu College of Pharmacy
2025
University of California San Francisco Medical Center
2016-2024
SRM Institute of Science and Technology
2024
JSS Academy of Higher Education and Research
2024
Osmania General Hospital
2024
Shri Venkateshwara University
2023
Akal University
2022
Crohn's and Colitis Foundation
2010-2017
University of Madras
2016
IntAct is an open-source, open data molecular interaction database populated by either curated from the literature or direct depositions. Two levels of curation are now available within database, with both IMEx-level annotation and less detailed MIMIx-compatible entries currently supported. As September 2011, contains approximately 275 000 binary evidences over 5000 publications. The website has been improved to enhance search process in particular graphical display results. New download...
Abstract The current wealth of genomic variation data identified at nucleotide level presents the challenge understanding by which mechanisms amino acid affects cellular processes. These effects may manifest as distinct phenotypic differences between individuals or result in development disease. Physical interactions molecules are linking steps underlying most, if not all, Understanding that sequence has on a molecule’s is key step towards connecting mechanistic characterization...
Although metronidazole and ciprofloxacin are used to treat perianal Crohn's disease (CD), no placebo-controlled trials have been performed.We performed a pilot trial evaluate the efficacy safety of in patients with CD. Twenty-five CD actively draining fistulas were randomized receive 500 mg, or placebo twice daily for 10 weeks. Remission response defined as closure all at least 50% that baseline, respectively. The primary endpoint was remission weeks.Ten ciprofloxacin, 7 metronidazole, 8...
Active inflammatory bowel disease increases the risk of adverse pregnancy outcomes. Tofacitinib is an oral, small molecule Janus kinase inhibitor for treatment ulcerative colitis (UC). As a molecule, tofacitinib likely to cross placental barrier; however, information on effects outcomes limited. We report and newborn among patients in UC clinical studies with prenatal (maternal/paternal) exposure tofacitinib. Pregnancies maternal/paternal were identified reported 5 interventional (up March...
Summary Background Vedolizumab is a gut‐selective immunoglobulin G 1 monoclonal antibody to α 4 β 7 integrin for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Prospective clinical studies vedolizumab in pregnancy have not been conducted; therefore, existing safety data were examined. Aim To assess outcomes females partners males who received vedolizumab. Methods All collected during programme (from 14 May 2007 27 June 2013) post‐marketing setting (to 19 November 2015)...
Objective Active inflammatory bowel disease (IBD) during pregnancy may require the use of corticosteroids. The aim this study was to investigate impact in utero corticosteroid exposure on adverse outcomes, congenital malformations, infections and neurocognitive development among offspring mothers with IBD. Design Using prospective Pregnancy Inflammatory Bowel Disease Neonatal Outcomes registry, data were collected at each trimester, delivery; 12 months post partum. Bivariate statistics...
Background: Pregnancy outcomes in patients with inflammatory bowel disease quiescent are similar to those the general population. Data from Inflammatory And Neonatal Outcomes registry have demonstrated safety of antitumor necrosis factor (TNF) α agents and thiopurines pregnancy. The objective this study was provide information on maternal fetal exposed newer biologics ustekinumab (UST) vedolizumab (VDZ). Methods: In multicenter prospective observational study, we included pregnant women...
This study evaluated pregnancy outcomes in patients with ulcerative colitis, Crohn’s disease, or multiple sclerosis and healthy volunteers treated ozanimod. There was no increased incidence of fetal abnormalities adverse ozanimod exposure during early pregnancy.
Abstract Background Women with inflammatory bowel disease (IBD) face complexities of management during pregnancy and childbirth. Apprehension regarding vaginal delivery in pregnant individuals IBD persists due to concern for perianal perineal trauma. The incidence poor wound healing after obstetric anal sphincter injury is approximately 4% the general population. In an population, risk developing difficulty tears episiotomy not well described. Methods a multicenter prospective cohort IBD, we...
Infliximab is effective for induction and maintenance of remission in reproductive age men with Crohn's disease. There no available data on the effects infliximab semen quality. The aim this study was to determine whether changes quality occurred receiving infliximab.In prospective study, each patient served as his own control. Patients completed general health fertility questionnaires were assessed disease activity. Two analyses before infusion 1 analysis week after infusion. Mean...